Home › Chronic Lymphocytic Leukemia › Missouri › Kansas City
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa Kansas City, MO
Isang pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Kansas City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Nagre-recruitPhase 3
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Nagre-recruitPhase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- at 1 pa
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Nagre-recruitPhase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- at 2 pa
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Nagre-recruitPhase 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nagre-recruitPhase 3
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nagre-recruitPhase 3
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Nagre-recruitPhase 3
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
- University of Kansas, Westwood · 5 mi ang layo
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Nagre-recruitPhase 2
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
Pag-aaral para sa Chronic Lymphocytic Leukemia sa ibang lungsod
- Boston, MA31 pag-aaral
- Columbus, OH28 pag-aaral
- Durham, NC27 pag-aaral
- Washington, DC22 pag-aaral
- Seattle, WA20 pag-aaral
- New York City, NY18 pag-aaral
- Rochester, MN18 pag-aaral
- Houston, TX17 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Milwaukee, WI15 pag-aaral
- Chicago, IL14 pag-aaral
- Cincinnati, OH14 pag-aaral
Iba pang pag-aaral sa Kansas City
- Kanser sa Suso34 pag-aaral
- Non-Small Cell Lung Cancer31 pag-aaral
- Pagkabigo ng Puso25 pag-aaral
- Kanser (lahat ng uri)21 pag-aaral
- Kanser sa Baga19 pag-aaral
- Colorectal Cancer16 pag-aaral
- Metastatic Cancer15 pag-aaral
- Acute Myeloid Leukemia15 pag-aaral
- Kanser sa Prostate14 pag-aaral
- Kanser sa Ovary11 pag-aaral
- Obesity11 pag-aaral
- Type 2 Diabetes11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.